Department of Neurogenetics, Max Planck Institute of Experimental Medicine, Göttingen, Germany
Dörte Hesse
Proteomics Group, Max Planck Institute of Experimental Medicine, Göttingen, Germany
Ramona B Jung
Department of Neurogenetics, Max Planck Institute of Experimental Medicine, Göttingen, Germany
Robert Fledrich
Department of Neurogenetics, Max Planck Institute of Experimental Medicine, Göttingen, Germany; Institute of Anatomy, University of Leipzig, Leipzig, Germany
Michael W Sereda
Department of Neurogenetics, Max Planck Institute of Experimental Medicine, Göttingen, Germany; Department of Clinical Neurophysiology, University Medical Center, Göttingen, Germany
Moritz J Rossner
Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
Peter J Brophy
Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
Proteome and transcriptome analyses aim at comprehending the molecular profiles of the brain, its cell-types and subcellular compartments including myelin. Despite the relevance of the peripheral nervous system for normal sensory and motor capabilities, analogous approaches to peripheral nerves and peripheral myelin have fallen behind evolving technical standards. Here we assess the peripheral myelin proteome by gel-free, label-free mass-spectrometry for deep quantitative coverage. Integration with RNA-Sequencing-based developmental mRNA-abundance profiles and neuropathy disease genes illustrates the utility of this resource. Notably, the periaxin-deficient mouse model of the neuropathy Charcot-Marie-Tooth 4F displays a highly pathological myelin proteome profile, exemplified by the discovery of reduced levels of the monocarboxylate transporter MCT1/SLC16A1 as a novel facet of the neuropathology. This work provides the most comprehensive proteome resource thus far to approach development, function and pathology of peripheral myelin, and a straightforward, accurate and sensitive workflow to address myelin diversity in health and disease.